论文部分内容阅读
目的:研究大剂量瑞舒伐他汀钙治疗老年冠心病合并高脂血症的临床疗效。方法:选取2013年10月到2014年10月我院收治的老年冠心病合并高脂血症患者110例,按照随机数字表法将患者分为研究组和对照组,每组55例。两组患者均给予常规治疗方法进行治疗,对照组增加5 mg瑞舒伐他汀钙进行治疗,研究组增加20 mg瑞舒伐他汀钙进行治疗,均每天1次,晚餐后应用,治疗时间为4个月。比较治疗前后两组血脂水平(胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白(LDL-C))及高密度脂蛋白(HDL-C)及其达标率以及不良反应。结果:治疗后两组TC、TG以及LDL-C均显著降低,HDL-C显著升高,且研究组优于对照组,比较差异具有统计学意义(P<0.05);研究组治疗后TC和LDL-C达标率显著高于对照组,两组比较差异具有统计学意义(P<0.05);两组不良反应发生率比较差异无统计学意义(P>0.05)。结论:大剂量瑞舒伐他汀钙治疗老年冠心病合并高脂血症具有较好的临床疗效,能显著降低患者的血脂水平。
Objective: To study the clinical efficacy of high-dose rosuvastatin calcium in the treatment of senile coronary heart disease complicated with hyperlipidemia. Methods: From October 2013 to October 2014, 110 elderly patients with coronary heart disease and hyperlipidemia admitted to our hospital were divided into study group and control group according to random number table method, with 55 cases in each group. Two groups of patients were given conventional treatment for treatment, the control group added 5 mg rosuvastatin calcium for treatment, the study group added 20 mg rosuvastatin calcium for treatment, were 1 day, after dinner, the treatment time was 4 Months. The levels of lipid (TC, TG, LDL-C) and HDL-C in both groups before and after treatment were compared with those of the control group and their adverse reactions. Results: The levels of TC, TG and LDL-C in both groups were significantly decreased and HDL-C significantly increased after treatment, and the difference between the two groups was statistically significant (P <0.05) LDL-C compliance rate was significantly higher than the control group, the difference between the two groups was statistically significant (P <0.05); the incidence of adverse reactions was no significant difference between the two groups (P> 0.05). Conclusion: The high-dose rosuvastatin calcium treatment of elderly patients with coronary heart disease with hyperlipidemia has a good clinical efficacy, can significantly reduce the patient’s blood lipid levels.